Bridgewater, NJ – May 6, 2026 – RVL Pharmaceuticals Inc. and its affiliates (together, “RVL”) announced strong first-quarter performance, with total revenue up double-digit year-over-year, led by Upneeq®. Results reflect accelerating consumer demand and continued momentum across RVL’s growth platform.
Read MoreBridgewater, NJ – May 1, 2026 – RVL Pharmaceuticals, the company behind Upneeq®, is expanding its presence into skincare with the launch of Upneeq Reveal™ Under Eye Complex, an expertly formulated under-eye treatment that brightens, firms, and smooths skin. This latest launch reflects the brand’s expansion into skincare, building on its established expertise in the eye area.
Read MoreBridgewater, NJ – January 8, 2026 – RVL Pharmaceuticals, Inc. and its affiliates (together, “RVL”) announces Santen Pharmaceutical Co., Ltd. (“Santen”), a leading ophthalmology company has obtained the manufacturing and marketing approval in Japan for UPNEEQ® Mini Ophthalmic Solution 0.1% (generic name: oxymetazoline hydrochloride; development code: STN1013800; hereinafter the product), a treatment for acquired blepharoptosis (low-lying eyelids).
Read MoreBridgewater, NJ – November 24, 2025 – RVL Pharmaceuticals Inc and its affiliates (together, “RVL”) today announced a series of senior leadership appointments to strengthen the organization and position the company for accelerated growth across its business, including its flagship product, Upneeq® (oxymetazoline hydrochloride ophthalmic solution), 0.1%.
Read More